This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Biogen Management
Management criteria checks 3/4
Biogen's CEO is Chris Viehbacher, appointed in Nov 2022, has a tenure of 3.58 years. total yearly compensation is $23.65M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth €4.96M. The average tenure of the management team and the board of directors is 4 years and 5 years respectively.
Key information
Chris Viehbacher
Chief executive officer
US$23.6m
Total compensation
CEO salary percentage
7.31%
CEO tenure
3.6yrs
CEO ownership
0.02%
Management average tenure
4yrs
Board average tenure
5yrs
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
How has Chris Viehbacher's remuneration changed compared to Biogen's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
US$1b
Dec 31 2025
US$24m
US$2m
US$1b
Sep 30 2025
n/a
n/a
US$2b
Jun 30 2025
n/a
n/a
US$2b
Mar 31 2025
n/a
n/a
US$1b
Dec 31 2024
US$24m
US$2m
US$2b
Sep 30 2024
n/a
n/a
US$2b
Jun 30 2024
n/a
n/a
US$1b
Mar 31 2024
n/a
n/a
US$1b
Dec 31 2023
US$4m
US$2m
US$1b
Sep 30 2023
n/a
n/a
US$1b
Jun 30 2023
n/a
n/a
US$3b
Mar 31 2023
n/a
n/a
US$3b
Dec 31 2022
US$30m
US$154k
US$3b
Compensation vs Market: Chris's total compensation ($USD23.65M) is above average for companies of similar size in the UK market ($USD7.48M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Viehbacher (65 yo)
3.6yrs
Tenure
US$23,646,004
Compensation
Mr. Christopher A. Viehbacher, also known as Chris, was President, Chief Executive Officer & Director of Biogen MA Inc. Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Christopher Viehbacher
President
3.6yrs
US$23.65m
0.020% € 5.0m
Robin Kramer
Executive VP & CFO
1.3yrs
US$5.81m
0.0078% € 1.9m
Nicole Murphy
Executive VP and Head of Pharmaceutical Operations & Technology
4.3yrs
US$7.58m
0.013% € 3.3m
Priya Singhal
Executive VP & Head of Development
6.4yrs
US$7.57m
0.0054% € 1.3m
Sean Godbout
VP, Chief Accounting Officer & Global Corporate Controller
1.3yrs
no data
0.00091% € 221.8k
Guy Hadari
Chief Information Officer
1.4yrs
no data
no data
Tim Power
Head of Investor Relations
1.5yrs
no data
no data
Adam Keeney
Executive VP & Head of Corporate Development
3.2yrs
no data
0.0043% € 1.1m
Ginger Gregory
Executive VP & Chief Human Resources Officer
8.9yrs
US$5.08m
0.015% € 3.7m
Alisha Alaimo
President & Head of North America
8.9yrs
no data
no data
Natacha Gassenbach
Chief Communication Officer & Head of Corporate Affairs
6.4yrs
no data
no data
Rachid Izzar
Executive VP and Head of Global Product Strategy & Commercialization
4.9yrs
US$5.45m
0.0075% € 1.8m
4.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: IDPD's management team is considered experienced (4 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Christopher Viehbacher
President
3.6yrs
US$23.65m
0.020% € 5.0m
Stephen A. Sherwin
Independent Director
16.3yrs
US$439.95k
0.0077% € 1.9m
William Hawkins
Independent Director
7yrs
US$462.45k
0.0044% € 1.1m
Caroline Dorsa
Independent Chair of the Board
16.4yrs
US$629.93k
0.019% € 4.6m
Eric Rowinsky
Independent Director
16.3yrs
US$454.95k
0.015% € 3.6m
Maria Freire
Independent Director
5yrs
US$457.45k
0.0030% € 733.5k
Lloyd Minor
Independent Director
1.7yrs
US$439.95k
0% € 0
Monish Patolawala
Independent Director
2.4yrs
US$447.45k
0.00091% € 221.8k
Menelas Nicolas Pangalos
Independent Director
1.4yrs
US$439.95k
0% € 0
Jesus Mantas
Independent Director
7yrs
US$459.95k
0.0050% € 1.2m
Susan Langer
Independent Director
3yrs
US$439.95k
0.0019% € 455.7k
5.0yrs
Average Tenure
67yo
Average Age
Experienced Board: IDPD's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/02 06:38
End of Day Share Price
2026/05/22 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biogen Inc. is covered by 58 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.